WaveMan
WaveMan · Company
BRVE · Braveheart Bio, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

BRVE Braveheart Bio (BRVE) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0002131524
Quote by TradingView
Cluster · 10 insidersActivist 13DC-suite buying · 3
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter
Conversions, 180 days
6
Codes C/M, not in net · $0 priced

What the filings say about BRVE

Insiders, 180 days
+$119.0M net bought
10 buyers
Activist stakes (13D), 180 days
2 filings
Largest: 17.2% of the class

Braveheart Bio insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Braveheart Bio, Inc. insiders bought a net $119.0M of stock across 10 Form 4 purchases and sales, with 10 insiders buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Viehbacher Christopher
Director
BUY
2026-08-07 SEC
83,333
$1.5M
-20.6%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 13.7% of the 609,519 shares held after it.
  • 9 other insiders bought within 30 days.
Insider activity: Director Viehbacher Christopher bought about $1.5M of BRVE on Aug 7, 2026, the largest insider purchase at the company on our record; 9 other insiders bought within 30 days.
Malek David I
Director
BUY
2026-08-07 SEC
4,166
$75.0K
-20.6%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 0.8% of the 533,845 shares held after it.
  • 9 other insiders bought within 30 days.
Insider activity: Director Malek David I bought about $75.0K of BRVE on Aug 7, 2026, the largest insider purchase at the company on our record; 9 other insiders bought within 30 days.
Anderson Michele A.
Chief Development Officer
BUY
2026-08-07 SEC
1,111
$20.0K
-20.6%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 0.3% of the 332,161 shares held after it.
  • 9 other insiders bought within 30 days.
Insider activity: Chief Development Officer Anderson Michele A. bought about $20.0K of BRVE on Aug 7, 2026, the largest insider purchase at the company on our record; 9 other insiders bought within 30 days.
Murdoch Travis
CEO and President
BUY
2026-08-07 SEC
83,333
$1.5M
-20.6%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 2.8% of the 2,940,670 shares held after it.
  • 9 other insiders bought within 30 days.
Insider activity: CEO and President Murdoch Travis bought about $1.5M of BRVE on Aug 7, 2026, the largest insider purchase at the company on our record; 9 other insiders bought within 30 days.
Lubner David Charles
Director
BUY
2026-08-07 SEC
55,555
$1.0M
-20.6%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 100.0% of the 55,555 shares held after it.
  • 9 other insiders bought within 30 days.
Insider activity: Director Lubner David Charles bought about $1,000.0K of BRVE on Aug 7, 2026, the largest insider purchase at the company on our record; 9 other insiders bought within 30 days.
10 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 5 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$119.0M over 180 days
+$119.0M over 90 days · +$114.4M of it by a 10%+ holder
the highest in Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
32.5% of the float short (float per yahoo 2026-10-26) · 5.1 days to cover · settled 2026-09-30
below 52% of Pharma & Biotech
The situation: each line is one rule over one dataset
ORBIMED ADVISORS LLC disclosed a 5%+ stake (17.2%) in the last six months.
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch BRVE

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-26.6%12M
-38%-25%-12%+1%2026-082026-082026-092026-092026-092026-102026-10 2026-08-07 · Forbion Growth Opportunities Fund III Cooperatief U.A. bought $34.6M2026-08-07 · ORBIMED ADVISORS LLC bought $30.0M2026-08-07 · Chimovits Erez bought $30.0M2026-08-07 · AH Bio Fund IV, L.P. bought $19.8M2026-08-07 · Viehbacher Christopher bought $1.5M2026-08-07 · Murdoch Travis bought $1.5M2026-08-07 · Lubner David Charles bought $1,000.0K2026-08-07 · Rickey James Paul bought $500.0K2026-08-07 · Malek David I bought $75.0K2026-08-07 · Anderson Michele A. bought $20.0K2026-08-18 · ORBIMED ADVISORS LLC filed a 5%+ stake (17.2%)2026-08-18 · OrbiMed Capital GP IX LLC filed a 5%+ stake (16.9%)2026-08-18 · OrbiMed Genesis GP LLC filed a 5%+ stake (0.4%)2026-08-14 · AH Bio Fund IV, L.P. filed a 5%+ stake (11.4%)2026-08-14 · AH Equity Partners Bio IV, L.L.C. filed a 5%+ stake (11.4%)2026-08-14 · Marc L. Andreessen filed a 5%+ stake (11.4%)2026-08-14 · Benjamin A. Horowitz filed a 5%+ stake (11.4%)
Insider buy13D/G stake
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns BRVE: institutional holders (13F)

13F holdings, latest reported quarter
SEC 13F
No reported 13F holders

No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.

Congress trades in BRVE

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

13D: intends to influence · 13G: passive
ORBIMED ADVISORS LLC
Activist 13D · 2026-08-18
17.2%
OrbiMed Capital GP IX LLC
Activist 13D · 2026-08-18
16.9%
OrbiMed Genesis GP LLC
Activist 13D · 2026-08-18
0.4%
AH Bio Fund IV, L.P.
Activist 13D · 2026-08-14
11.4%
AH Equity Partners Bio IV, L.L.C.
Activist 13D · 2026-08-14
11.4%

BRVE planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Clinical pipeline
1 registered trials, 1 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Phase 3
1 active
What changed recently
BHB-1893 Versus Metoprolol for Symptomatic Obstructive Hypertrophic Cardiomyopathy
2026-10-03 · Not Yet Recruiting → Recruiting
Phase 3
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
10 insiders reported buying shares.
The record shows a net $119.0M bought by insiders over 180 days. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

BRVE Stock Sonar score 2/7 axes

Find similar shapesCompare
Insider conviction
100
Inputs
  • Net Form 4 buying (codes P and S), 180d$119.0M · 100 pct, sector of 428
  • Insider buyers, 180d10 · 100 pct, sector of 437
Risk and compliance
3
Inputs
  • Short interest, % of float+32.5% · 3 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
5 not measured: Profitability, Financial health, Growth, Institutional and government, US patents
  • Profitability needs 2 of 4 inputs, 0 present: fewer than four consecutive quarters of net income; fewer than four consecutive quarters of operating income
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

2 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

BRVE filings, in plain words

Are Braveheart Bio insiders buying or selling BRVE?

In the 180 days to 2026-10-27, Braveheart Bio insiders were net buyers, a net $119.0M across purchases and sales reported on Form 4, by 10 buyers.

Read the full summary

In the 180 days to 2026-10-27, Braveheart Bio insiders were net buyers of BRVE, a net $119.0M across purchases and sales reported on Form 4 by 10 buyers. Most of that figure, $114.4M, came from a holder of 10% or more rather than an officer or director. 10 different insiders reported purchases within the last 90 days, a cluster buy, which is rarer than a single purchase. 2 activist Schedule 13D filings in the last 180 days declared an intent to influence the company, the largest for 17.2% of the class. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies